Pfizer Inc. recently announced that its Xeljanz drug for treating moderate to severe active rheumatoid arthritis (RA) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Read More »
A Nevada bill headed to the desk of Governor Brian Sandoval (R) would do nothing to decrease prescription drug costs, according to the Council of Citizens Against Government Waste (CCAGW). Read More »
Panacea Pharmaceuticals has filed a U.S. patent application for Immune System Enhancing Immunotherapy for the treatment of cancer. Read More »
Endo International plc recently announced that one of its operating companies, Endo Pharmaceuticals Inc. based in Malvern, Pennsylvania, is voluntarily recalling one lot of Edex (alprostadil) for injection because the company detected a defect in the crimp caps used in the manufacture of the subject product lot. Read More »
DelMar Pharmaceuticals recently hosted a Key Opinion Leader forum at the Lotte New York Palace Hotel in New York City, highlighting its novel treatment for patients suffering from glioblastoma multiforme. Read More »
Six finalists of the Sandoz HACk presented their ideals to a panel of judges at WIRE Health in London. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently shared the results of a Phase 3 Chronos study as a late-breaking abstract at the annual meeting of the American Academy of Dermatology. Read More »
CVS Health recently released a report highlighting the health care needs of an aging population, noting that Americans are living longer than ever before. Read More »
GSK has submitted a supplemental Biologics License Application for Fluarix Quadrivalent (influenza vaccine) to the U.S. Food and Drug Administration. Read More »
Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio was approved by the Food and Drug Administration for intravenous use. Read More »
Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s 66th Annual Scientific Session & Expo. Read More »
Sanofi and Regeneron Pharmaceuticals Inc. recently presented Phase 3 clinical trial data and multiple additional analyses from the Praluent (alirocumab) Injection's Odyssey clinical trial program at the American College of Cardiology Scientific Sessions in Washington, D.C. Read More »
Protagonist Therapeutics Inc., announced May 30 that they have formed a worldwide license and collaboration with Janssen Biotech Inc. Read More »
Biohaven Pharmaceutical Holding Company Ltd. has finished its enrollment in the clinical study for trigriluzole for individuals with spinocerebellar ataxia, a rare neurodegenerative disorder. Read More »
Diplomat Pharmacy Inc. is now filling prescriptions for KEVZARA (sarilumab), an FDA-approved medication for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who are intolerant to or not receiving enough of a response from other disease modifying antirheumatic drugs. Read More »
Innovus Pharmaceuticals Inc. is signing an exclusive license and distribution agreement for commercialization of Zestra and Zestra Glide with Luminarie Pty Ltd. throughout Australia, New Zealand and the Philippines. Read More »
Sierra Oncology has been granted a selection patent for its Chk1 inhibitor, SRA737 by the U.S. Patent and Trademark Office. Read More »
According to the Technavio’s latest market study, the North American pharmaceutical packaging market is expected to grow through 2021. Read More »
The Pharmaceutical Care Management Association (PCMA) released a statement in support of the Food and Drug Commissioner’s call to publish a list of off-patent drugs that may be vulnerable to price-fixing. Read More »
BioPharma Services Inc. recently passed three Food and Drug Administration inspections without a single Form 483 being issued. Read More »
Alerts Sign-up
